Related Experiment Video
Updated: Jun 3, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Changes in prostate specific antigen value in patients with COVID-19
Yildiray Yildiz1, Veysel Bayburtluoglu1, Eda Tokat1
1Department of Urology, Clinic of Ankara Training and Research Hospital, Ankara, Turkey.
Objectives:
To evaluate changes in prostate-specific antigen (PSA) values in patients with coronavirus disease 2019 (COVID-19).
Method:
Male patients who were admitted to our flu outpatient clinic with cough, fever, weakness, and bone and joint pain were evaluated. The acute phase reactants of erythrocyte sedimentation rate, C-reactive protein, ferritin, and fibrinogen were measured both at the time the patients first presented at the clinic and 1 month after recovery from COVID-19 infection. PSA and free PSA were also measured at the same time. The difference in acute phase reactants and PSA values during active COVID-19 infection and after recovery was assessed using the paired samples t-test.
Results:
The mean PSA values of the patients were 2.73 ± 3.7 μg/L in the period of active infection, and 2.04 ± 2.32 μg/L 1 month later (p = 0.12). In the 29 patients with PSA values in the gray zone, the PSA values were determined as 6.6 ± 4.4 μg/L during infection and 4.1 ± 2.9 μg/L after treatment (p = 0.001).
Conclusion:
The results of this study showed that PSA values in the gray zone during COVID-19 infection decreased after treatment when the patient recovered.
